Asrar Khan Waseem, Woodhead Mark
Department of Respiratory Medicine, Manchester Royal Infirmary Manchester.
F1000Prime Rep. 2013 Oct 1;5:43. doi: 10.12703/P5-43.
This article is a non-systematic review of selected recent publications in community-acquired pneumonia, including a comparison of various guidelines. Risk stratification of patients has recently been advanced by the addition of several useful biomarkers. The issue of single versus dual antibiotic treatment remains controversial and awaits a conclusive randomized controlled trial. However, in the meantime, there is a working consensus that more severe patients should receive dual therapy.
本文是对近期有关社区获得性肺炎的部分出版物的非系统性综述，包括对各种指南的比较。近期通过增加几种有用的生物标志物，患者的风险分层有了进展。单药治疗与联合抗生素治疗的问题仍存在争议，有待一项结论性的随机对照试验。然而，与此同时，目前有一个可行的共识，即病情较重的患者应接受联合治疗。
